Pneumolysin binds to the mannose receptor C type 1 (MRC-1) leading to anti-inflammatory responses and enhanced pneumococcal survival.


Journal

Nature microbiology
ISSN: 2058-5276
Titre abrégé: Nat Microbiol
Pays: England
ID NLM: 101674869

Informations de publication

Date de publication:
01 2019
Historique:
received: 07 02 2018
accepted: 01 10 2018
pubmed: 14 11 2018
medline: 18 6 2019
entrez: 14 11 2018
Statut: ppublish

Résumé

Streptococcus pneumoniae (the pneumococcus) is a major cause of mortality and morbidity globally, and the leading cause of death in children under 5 years old. The pneumococcal cytolysin pneumolysin (PLY) is a major virulence determinant known to induce pore-dependent pro-inflammatory responses. These inflammatory responses are driven by PLY-host cell membrane cholesterol interactions, but binding to a host cell receptor has not been previously demonstrated. Here, we discovered a receptor for PLY, whereby pro-inflammatory cytokine responses and Toll-like receptor signalling are inhibited following PLY binding to the mannose receptor C type 1 (MRC-1) in human dendritic cells and mouse alveolar macrophages. The cytokine suppressor SOCS1 is also upregulated. Moreover, PLY-MRC-1 interactions mediate pneumococcal internalization into non-lysosomal compartments and polarize naive T cells into an interferon-γ

Identifiants

pubmed: 30420782
doi: 10.1038/s41564-018-0280-x
pii: 10.1038/s41564-018-0280-x
pmc: PMC6298590
mid: EMS79869
doi:

Substances chimiques

Bacterial Proteins 0
Forkhead Transcription Factors 0
Foxp3 protein, mouse 0
IFNG protein, mouse 0
MRC1 protein, human 0
Membrane Glycoproteins 0
RNA, Small Interfering 0
Receptors, Immunologic 0
Socs1 protein, mouse 0
Streptolysins 0
Suppressor of Cytokine Signaling 1 Protein 0
Virulence Factors 0
plY protein, Streptococcus pneumoniae 0
Interleukin-4 207137-56-2
Interferon-gamma 82115-62-6

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

62-70

Subventions

Organisme : Wellcome Trust
ID : 204457/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P011284/1
Pays : United Kingdom

Références

Trends Immunol. 2005 Feb;26(2):104-10
pubmed: 15668126
Nat Rev Microbiol. 2008 Apr;6(4):288-301
pubmed: 18340341
Glycobiology. 2006 May;16(5):422-30
pubmed: 16423983
J Immunol. 2003 Nov 1;171(9):4552-60
pubmed: 14568928
Infect Immun. 1984 Mar;43(3):1085-7
pubmed: 6698602
Nat Rev Immunol. 2014 Feb;14(2):94-108
pubmed: 24445665
J Exp Med. 2005 Oct 3;202(7):987-99
pubmed: 16203868
mBio. 2013 Sep 10;4(5):e00655-13
pubmed: 24023386
BMC Microbiol. 2014 Aug 02;14:211
pubmed: 25085553
Annu Rev Immunol. 2000;18:143-64
pubmed: 10837055
Nat Rev Immunol. 2007 Jun;7(6):454-65
pubmed: 17525754
Neurosci Res. 2011 Apr;69(4):308-13
pubmed: 21192991
Lancet. 2010 Jun 5;375(9730):1969-87
pubmed: 20466419
Am J Respir Crit Care Med. 2014 May 15;189(10):1250-9
pubmed: 24749506
Cell Host Microbe. 2017 Jan 11;21(1):73-83
pubmed: 28081446
PLoS Pathog. 2010 Nov 11;6(11):e1001191
pubmed: 21085613
J Biol Chem. 2002 Nov 1;277(44):41613-23
pubmed: 12196537
J Immunol. 2007 Apr 15;178(8):4975-83
pubmed: 17404279
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
Nat Rev Immunol. 2003 Jan;3(1):23-35
pubmed: 12511873
Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2897-902
pubmed: 17301241
J Infect Dis. 2008 Mar 1;197(5):744-51
pubmed: 18260758
Eur J Immunol. 2006 May;36(5):1074-82
pubmed: 16619293
EMBO Mol Med. 2009 Jul;1(4):211-22
pubmed: 20049723
J Immunol. 2013 Jan 1;190(1):250-8
pubmed: 23197261
Infect Immun. 1989 Jul;57(7):2037-42
pubmed: 2731982
Infect Immun. 1991 Jul;59(7):2297-304
pubmed: 2050399
J Bacteriol. 2009 Apr;191(7):2163-8
pubmed: 19168620
Cell Rep. 2017 Oct 3;21(1):126-140
pubmed: 28978467
Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10649-54
pubmed: 27601670

Auteurs

Karthik Subramanian (K)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Daniel R Neill (DR)

Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.

Hesham A Malak (HA)

Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.

Laura Spelmink (L)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Shadia Khandaker (S)

Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.

Giorgia Dalla Libera Marchiori (G)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Emma Dearing (E)

Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.

Alun Kirby (A)

Centre for Immunology and Infection, Department of Biology and Hull York Medical School, University of York, York, UK.

Marie Yang (M)

Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.

Adnane Achour (A)

Science for Life Laboratory, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Department of Infectious Diseases, Karolinska University Hospital Solna, Stockholm, Sweden.

Johan Nilvebrant (J)

Division of Protein Technology, School of Biotechnology, Royal Institute of Technology (KTH), Stockholm, Sweden.

Per-Åke Nygren (PÅ)

Division of Protein Technology, School of Biotechnology, Royal Institute of Technology (KTH), Stockholm, Sweden.

Laura Plant (L)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Aras Kadioglu (A)

Institute of Infection and Global Health, University of Liverpool, Liverpool, UK. a.kadioglu@liverpool.ac.uk.

Birgitta Henriques-Normark (B)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. birgitta.henriques@ki.se.
Clinical Microbiology, Karolinska University Hospital Solna, Stockholm, Sweden. birgitta.henriques@ki.se.
Lee Kong Chian School of Medicine (LKC) and Singapore Centre on Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singapore, Singapore. birgitta.henriques@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH